NASDAQ:OTLK

Outlook Therapeutics Stock Earnings Reports

etoro logo Buy OTLK
*Your capital is at risk
$1.58
-0.0700 (-4.24%)
At Close: Jun 18, 2026

Outlook Therapeutics Earnings Calls

Mar 31, 2026
-$0.160 (-33.33%)
Release date May 15, 2026
EPS estimate -$0.120
EPS actual -$0.160
EPS Surprise -33.33%
Revenue estimate 4.39M
Revenue actual 128K
Revenue Surprise -97.08%
Dec 31, 2025
-$0.220 (-29.41%)
Release date Feb 17, 2026
EPS estimate -$0.170
EPS actual -$0.220
EPS Surprise -29.41%
Revenue estimate 3.143M
Revenue actual -1208000
Revenue Surprise -138.44%
Sep 30, 2025
-$0.220 (15.38%)
Release date Dec 19, 2025
EPS estimate -$0.260
EPS actual -$0.220
EPS Surprise 15.38%
Revenue estimate 5.84M
Revenue actual -91787
Revenue Surprise -101.57%
Jun 30, 2025
-$0.440 (-4.76%)
Release date Aug 14, 2025
EPS estimate -$0.420
EPS actual -$0.440
EPS Surprise -4.76%
Revenue estimate 5.846M
Revenue actual 1.505M
Revenue Surprise -74.25%

Last 4 Quarters for Outlook Therapeutics

Below you can see how OTLK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Missed
Release date Aug 14, 2025
Price on release $2.43
EPS estimate -$0.420
EPS actual -$0.440
EPS surprise -4.76%
Date Price
Aug 08, 2025 $1.90
Aug 11, 2025 $1.96
Aug 12, 2025 $2.09
Aug 13, 2025 $2.13
Aug 14, 2025 $2.43
Aug 15, 2025 $2.34
Aug 18, 2025 $2.77
Aug 19, 2025 $2.63
Aug 20, 2025 $2.39
4 days before 27.89%
4 days after -1.65%
On release day -3.70%
Change in period 25.79%
Sep 30, 2025 Beat
Release date Dec 19, 2025
Price on release $2.01
EPS estimate -$0.260
EPS actual -$0.220
EPS surprise 15.38%
Date Price
Dec 15, 2025 $2.16
Dec 16, 2025 $2.47
Dec 17, 2025 $2.27
Dec 18, 2025 $2.07
Dec 19, 2025 $2.01
Dec 22, 2025 $1.84
Dec 23, 2025 $1.86
Dec 24, 2025 $1.83
Dec 26, 2025 $1.82
4 days before -6.94%
4 days after -9.45%
On release day -8.46%
Change in period -15.74%
Dec 31, 2025 Missed
Release date Feb 17, 2026
Price on release $0.422
EPS estimate -$0.170
EPS actual -$0.220
EPS surprise -29.41%
Date Price
Feb 10, 2026 $0.421
Feb 11, 2026 $0.469
Feb 12, 2026 $0.441
Feb 13, 2026 $0.479
Feb 17, 2026 $0.422
Feb 18, 2026 $0.410
Feb 19, 2026 $0.435
Feb 20, 2026 $0.413
Feb 23, 2026 $0.400
4 days before 0.333%
4 days after -5.28%
On release day -3.01%
Change in period -4.97%
Mar 31, 2026 Missed
Release date May 15, 2026
Price on release $0.228
EPS estimate -$0.120
EPS actual -$0.160
EPS surprise -33.33%
Date Price
May 11, 2026 $0.248
May 12, 2026 $0.243
May 13, 2026 $0.230
May 14, 2026 $0.233
May 15, 2026 $0.228
May 18, 2026 $0.229
May 19, 2026 $0.228
May 20, 2026 $0.273
May 21, 2026 $0.333
4 days before -7.91%
4 days after 45.99%
On release day 0.482%
Change in period 34.44%

Outlook Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for OTLK?
Outlook Therapeutics Inc. (OTLK) has scheduled its earnings report for Aug 13, 2026 before the markets open.

What is the OTLK price-to-earnings (P/E) ratio?
OTLK P/E ratio as of Jun 18, 2026 (TTM) is -2.22.

What is the OTLK EPS forecast?
The forecasted EPS (Earnings Per Share) for Outlook Therapeutics Inc. (OTLK) for the first fiscal quarter 2026 is -$0.0900.

What are Outlook Therapeutics Inc.'s retained earnings?
On its balance sheet, Outlook Therapeutics Inc. reported retained earnings of $128.00 thousand for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
7.76% Jun 12
DHI
$146.71
7.57% Jun 10
PHM
$118.49
7.15% Jun 10
EAT
$140.46
17.39% Jun 05
TPR
$140.47
2.16% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE